Rapid Biosensor Systems appoints chair in move to IPO

12 August 2014

Cambridge company Rapid Biosensor Systems Ltd has appointed John Reynolds OBE as Executive Chairman to take it to the next stage of growth.

The company has developed a unique breathalyser technology for the screening of active tuberculosis that can be used in any type of location to give rapid low-cost results.

Reynolds has chaired the Church of England’s Ethical Investment Advisory Group, is a director of a number of companies, including Northern Powergrid Holding Company and the Central Finance Board of the Methodist Church, and was awarded an OBE in 2012 in recognition for his services to Save the Children.

He has extensive experience of advising and financing companies from early stage to Fortune 500 in the UK, Europe, Asia and the US, and has led the sale of pre-revenue companies for major financial investors as well as FTSE100 corporates.

Dennis Camilleri CEO and Co-Founder of Rapid Biosensor said: “We are delighted to have the opportunity to work with John who is already creating significant traction with global investment groups. Our company has successfully tested its product in India and Ethiopia, and the results indicate it will make a real contribution to healthcare improvements worldwide. The technology will also provide the basis for other medical devices and the company is preparing for an IPO in the near future.

About the technology

The RBS TB Breathalyser incorporates a range of technologies that allow for full portability and almost instant results. It can be assembled without the need for clean room conditions and may be used by non-medical personnel, so is particularly suitable for use in developing countries.

The breathalyser incorporates a single-use disposable sample collection tube (10cm x 3.5cm) and a multi-use reader. After being nebulised (if necessary) using a 0.9% saline solution, the patient then coughs into the collection tube, at the bottom of which is a glass bio-sensor coated with a patented bio-chemical coating formulated to react with the TB bacilli. A simple push-and-twist action automatically seals the aerosol sample in the tube and deposits it on the bio-sensor. The tube is then inserted into the reader and twisted to switch on the unit.

The biochemical coating contains fluorescent chemicals that are displaced by TB antigen and so when excited by the laser return a reduced signal if TB is present in the sample. The laser detects this signal change and the unit returns a positive result. Reading and analysis of the sample takes about two minutes.

Website: www.rapidbiosensor.com

Source: Rapid Biosensor systems


To top